

## EQA round: CSFB1/25 - Cerebrospinal Fluid Analysis

Deadline: 7.2.2025

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D <sub>max</sub> = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N <sub>tot</sub> = total number of the results		N <sub>eva</sub> = number of the results assessed
N <sub>out</sub> = number of the results removed before calculation		N <sub>suc</sub> = number of successful results
		S <sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(333) Albumin</b>	[mg/L]				14							14	14	100	
<b>Sample A</b>		235	14	5,8	14		CVP	239	5,3	23%	184	294	14	14	100
(58) Beckman Coulter (AU)		235	5,9	2,5	5	0							5		
Other					9	0							9		
							1x 12, 2x 60, 1x 91, 3x 149, 1x 162, 1x 179								
<b>Sample B</b>		345	22	6,4	14		CVP	349	7,4	23%	268	430	14	14	100
(58) Beckman Coulter (AU)		349	4,5	1,3	5	0							5		
Other					9	0							9		
							1x 12, 2x 60, 1x 91, 3x 149, 1x 162, 1x 179								
<b>(330) Total protein</b>	[mg/L]				15								15	15	100
<b>Sample A</b>		398	21	5,3	15		CVP	407	6,4	27%	297	517	15	15	100
(58) Beckman Coulter (AU)		412	17	4,2	6	0							6		
Other					9	0							9		
							1x 1, 3x 60, 1x 75, 1x 77, 1x 85, 1x 178, 1x 998								
<b>Sample B</b>		1060	71	6,7	15		CVP	1030	11	27%	751	1310	15	15	100
(58) Beckman Coulter (AU)		1080	57	5,3	6	0							6		
Other					9	0							9		
							1x 1, 3x 60, 1x 75, 1x 77, 1x 85, 1x 178, 1x 998								
<b>(331) Glucose</b>	[mmol/L]				15								15	15	100
<b>Sample A</b>		3,24	0,076	2,3	15		CVP	3,28	0,024	18%	2,68	3,88	15	15	100
(58) Beckman Coulter (AU)		3,25	0,067	2,1	7	0							7		
Other					8	0							8		
							3x 46, 3x 60, 1x 75, 1x 188								
<b>Sample B</b>		1,69	0,04	2,4	15		CVP	1,7	0,01	18%	1,39	2,01	15	15	100
(58) Beckman Coulter (AU)		1,69	0,035	2,1	7	0							7		
Other					8	0							8		
							3x 46, 3x 60, 1x 75, 1x 188								
<b>(335) IgA</b>	[mg/L]				4								4	2	50
<b>Sample A</b>		10	2,5	25	4		CVP	10	0,4	32%	6,8	13,2	4	4	100
Other					4	0							4		
							1x 12, 1x 91, 2x 149								
<b>Sample B</b>		42,2	21	50	4		CVP	37	5,1	32%	25,1	48,9	4	2	50
Other					4	0							4		
							1x 12, 1x 91, 2x 149								
<b>(334) IgG</b>	[mg/L]				10								10	10	100
<b>Sample A</b>		60,6	3,1	5,2	10		CVP	59,3	1,2	24%	45	73,6	10	10	100
Other					10	0							10		
							1x 12, 1x 58, 1x 60, 2x 91, 4x 149, 1x 162								
<b>Sample B</b>		461	23	4,9	10		CVP	460	8,4	24%	349	571	10	10	100
Other					10	0							10		
							1x 12, 1x 58, 1x 60, 2x 91, 4x 149, 1x 162								
<b>(336) IgM</b>	[mg/L]				5								5	4	80
<b>Sample A</b>		4,21	0,38	9	5		CVP	4,07	0,17	31%	2,8	5,34	5	5	100
Other					5	0							5		
							1x 12, 1x 91, 3x 149								
<b>Sample B</b>		15,9	1,4	8,7	5		CVP	15,5	0,71	31%	10,6	20,4	5	4	80
Other					5	0							5		
							1x 12, 1x 91, 3x 149								
<b>(338) Lactate</b>	[mmol/L]				15								15	14	93
<b>Sample A</b>		1,89	0,069	3,7	15		CVP	1,92	0,016	20%	1,53	2,31	15	15	100
(58) Beckman Coulter (AU)		1,87	0,022	1,2	6	0							6		
Other					9	0							9		
							1x 1, 4x 60, 1x 75, 1x 178, 2x 188								
<b>Sample B</b>		3,84	0,13	3,5	15		CVP	3,86	0,026	20%	3,08	4,64	15	14	93
(58) Beckman Coulter (AU)		3,81	0,082	2,1	6	0							6		
Other					9	0							9		
							1x 1, 4x 60, 1x 75, 1x 178, 2x 188								